Literature DB >> 32343162

Conducting clinical trials during the COVID-19 pandemic.

Erin K Collier1, Jennifer L Hsiao2, Vivian Y Shi3.   

Abstract

The COVID-19 pandemic has greatly impacted dermatology clinical trial operations due to mandated governmental and institutional shut-downs and newly implemented restrictions. During this unprecedented time, measures should be taken to maintain research conduct compliance while also ensuring the safety of trial staff and participants. Herein, we underscore the challenges facing dermatology trials during the COVID-19 pandemic, and offer strategies to maintain compliant and safe conduct.

Entities:  

Keywords:  COVID-19; Clinical trials; compliance; safety

Mesh：

Year:  2020        PMID： 32343162     DOI： 10.1080/09546634.2020.1759770

Source DB:  PubMed          Journal:  J Dermatolog Treat        ISSN： 0954-6634            Impact factor:   3.359


  5 in total

Review 1.  Landscape of humoral immune responses against SARS-CoV-2 in patients with COVID-19 disease and the value of antibody testing.

Authors:  Sundarasamy Mahalingam; John Peter; Ziyang Xu; Devivasha Bordoloi; Michelle Ho; Vaniambadi S Kalyanaraman; Alagarsamy Srinivasan; Kar Muthumani
Journal:  Heliyon       Date:  2021-04-17

2.  Effectively Conducting Oncology Clinical Trials During the COVID-19 Pandemic.

Authors:  Debra Nana Yeboa; Chidinma Anakwenze Akinfenwa; Jonathan Nguyen; Diana Amaya; Beth de Gracia; Matthew Ning; Victoria Cox; Brian De; Benjamin D Smith; Lili Lin; Sam Beddar; Hanh Hoang; Albert Koong; Zhongxing Liao
Journal:  Adv Radiat Oncol       Date:  2021-03-03

3.  The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic.

Authors:  Hans H Liu; Michael D Ezekowitz; Michele Columbo; Oneib Khan; Jack Martin; Judith Spahr; David Yaron; Lisa Cushinotto; Luciano Kapelusznik
Journal:  Trials       Date:  2021-09-07       Impact factor: 2.279

4.  Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate to severe ARDS in a randomized, placebo-controlled, double-blind trial: preliminary evaluation of safety and feasibility in light of the COVID-19 pandemic.

Authors:  Benedikt Schmid; Peter Kranke; Rudolf Lucas; Patrick Meybohm; Bernhard Zwissler; Sandra Frank
Journal:  Trials       Date:  2022-04-04       Impact factor: 2.279

5.  Impact of the COVID-19 pandemic on recruitment to clinical research studies in rheumatology.

Authors:  Mazin Mirza; Stefan Siebert; Arthur Pratt; Elspeth Insch; Frances McIntosh; John Paton; Claire Wright; Christopher D Buckley; John Isaacs; Iain B McInnes; Karim Raza; Marie Falahee
Journal:  Musculoskeletal Care       Date:  2021-05-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.